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Abstract
Background: The aim of this study was to examine the potential biomechanical and histological benefits of
systemic erythropoietin administration during the healing of Achilles tendon injury in a rat experimental model.
Methods: Eighty Sprague-Dawley female rats were included in this study. Animals were randomly assigned into
two groups with 40 animals in each: erythropoietin group and control group. Then each group was further divided
into four subgroups corresponding to four time points with 10 animals in each. A full-thickness cut was made on
the Achilles tendon of each animal and then the tendon was sutured with modified Kessler method. Erythropoietin
groups received intraperitoneal erythropoietin (500 IU/kg/day) every day at same time throughout the study period,
and the control groups received saline in a similar manner. Animals were sacrificed at four time points, and tensile
test was performed on each tendon sample to assess maximum load for each sample. In addition, histopathological
examination and scoring was done.
Results: Both groups had improvement on tensile test (maximum load) over time. However, groups did not differ
with regard to maximum load in any of the time points. Similarly, groups did not differ with regard to any of the
histopathological scores over time.
Conclusions: The findings of this study do not support the benefit of systemic erythropoietin administration in
Achilles tendon healing process. Further evidence from larger experimental studies is required to justify any such
potential benefit.
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Background
The tendons are strong structures that have to resist high
tension loads, and healing of tendon injuries are of special
concern in practice. Tendon healing is relatively a slower
process when compared to other connective tissue struc-
tures, and the main goal of the treatment of tendon injur-
ies is to restore mechanical strength. The Achilles tendon
is the thickest and the strongest tendon in the body [1, 2],
and it has important role in locomotion.
Erythropoietin is a 34-kD glycoprotein hormone that
regulates the development of erythrocytes in the bone
marrow through binding a high affinity receptor expressed
on erythroid progenitor cells. Owing to its hematopoietic
properties, erythropoietin has been used in the treatment
of patients with chronic renal disease or chemotherapy-
associated anemia. In addition, erythropoietin receptor is
expressed on other cell types, suggesting other roles for
this hormone. Further research identified its potential
antioxidant [3], anti-apoptotic [4], anti-inflammatory [5],
angiogenic [6], neuroprotective [7], and enhanced wound
healing effects [8]. Its role in wound healing has been
tested in many studies using different soft tissue injury
* Correspondence: okkesbilal@gmail.com
1Department of Orthopaedics and Traumatology, Sutcu Imam University
Medical Faculty, Kahramanmaras, Turkey
Full list of author information is available at the end of the article
© 2016 Bilal et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bilal et al. Journal of Orthopaedic Surgery and Research  (2016) 11:55 
DOI 10.1186/s13018-016-0390-1
models [8–11]. However, studies testing its role in the
healing of tendon injuries are relatively scarce [12].
Tensile strength test is a useful test to examine bio-
mechanical properties of tissues. During this test, the
sample material is pulled and its ability to preserve its
integrity is measured. A full tensile profile can be ob-
tained when the test is continued until the failure of the
material. Increased angiogenesis is a part of repair
process of the injured tissues, and histological examin-
ation provides information on the level of revasculariza-
tion during healing.
The aim of this study was to examine the role of sys-
temic erythropoietin administration in the healing of an
experimental Achilles tendon injury as assessed by
tensile strength test and histopathological evaluation.
Methods
Experimental animals
Eighty Sprague-Dawley female rats weighing between
200 and 350 g were included in this study. The study
was conducted at the Experimental Research Laboratory
of Sutcu Imam University, Kahramanmaras, Turkey. The
study protocol was approved by the local ethics commit-
tee for animal experiments of Kahramanmaras Sutcu
Imam University Medical Faculty (reference number:
06.03.2013/02). The animals were kept at a standard ani-
mal care environment and fed with standard animal
food. Animals were first randomly assigned into two
groups with 40 animals in each: erythropoietin group
(group E) and control group (group C). Then each group
was further divided into four subgroups corresponding
to four time points with 10 animals in each (groups E1
to E4 and groups C1 to C4).
Surgical procedures
Subjects were anesthetized with intramuscular ketamine
HCl 200 mg/kg (Ketalar® Eczacibasi, Turkey) and xyla-
zine 1 mg/kg (RompunR, Bayer, Turkey). A single dose
of 0.1 mg/kg intramuscular cefazolin sodium (Cefozin,
Bilim Ilac, Turkey) was administered for infection
prophylaxis prior to surgical interventions.
The right hind legs of animals were shaved, betadine
was applied, and surgical site was covered with a sterile
dressing. A 3-cm incision was made over the Achilles
tendon, and the peritendon was opened. A full-thickness
cut was made on the Achilles tendon approximately
0.5 cm above its insertion to the calcaneus. The plantaris
tendon was also cut to avoid splint effect. Then the
Achilles tendon was sutured using 6/0 monofilament
polydioxanone suture material (PDS®, Ethicon Inc.,
Bridgewater, NJ, US) with modified Kessler method. The
skin was closed using 4/0 monofilament suture material
(Prolene®, Ethicon Inc., Bridgewater, NJ, US). Figure 1
shows the technique for cutting and repair of the
tendons. Rats were allowed to have free cage movement
after surgery.
Study interventions and sampling
The same investigator administered intraperitoneal
erythropoietin (500 IU/kg/day) every day at same time
throughout the study period to the rats in the erythro-
poietin group. Control group received the same volume
of isotonic NaCl in a similar manner every day.
Ten animals from each treatment group (erythropoi-
etin and controls) were sacrificed with high dose of
pentobarbital anesthesia at weeks 1, 2, 3, and 4. The
Achilles tendons of the subjects were removed, seven of
them were used for biomechanical experiments and
the remaining three were used for histopathological
examination. Histopathological specimens were kept
in formaldehyde solution until examination. The
remaining specimens were kept at −80 ° C prior to
biomechanical tests.
Assessments
Tensile strength tests were done with ZWICK ROELL Z
5.0 device. In order to prevent tendon damage and slip-
ping, non-slipping pads consisting of 2-mm thick rubber
plates covered with sand paper were used to fix the ten-
dons to the clamps with a cyanoacrylate adhesive (303-A
Bruno®). Proximal and distal tips of the tendons were
placed between the clamps with pads and they were
tightened using six bars of pneumatic pressure. The dis-
tance between the clamps was adjusted to obtain a ten-
don length of 5 cm, and the rate of the device was set at
0.1 mm/s for the tensile test. In order to achieve an
equal length and parallel alignment of the collagen fi-
bers, a pre-loading under a standard load of 1 N was
performed for 1 min prior to testing. Then, the ten-
sile test was performed until tendon failure. TestXpert
II software was used for data analysis, and a stress
(applied force) versus strain (change in length) graph
was constructed to estimate maximum load in
Newtons for each sample.
Histological samples were taken from a plane adjacent
to the suture site where macroscopically healing reaction
was evident; and 3- to 5-μm thin sections were prepared
after formalin fixation. Then preparations were stained
with hematoxylin-eosin and Masson’s trichrome stains
for examination under light microscope and assessments
were done. Tissue revascularization, inflammation, fiber
structures [13], and hyaline degeneration [13] were
scored semi-quantitatively using a 0- to 3-point scale as
defined in Table 1. In addition, a number of active fibro-
blasts were evaluated as follows: mesenchymal cells with
irregular cytoplasm, ovoid and large light staining
nucleus, and marked nucleolus were counted at three
×40 magnification fields and the mean of three
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measurements was used for analysis [14]. Histopatho-
logical examination was done by a single pathologist
blinded to the study subjects.
Statistical analysis
SPSS version 21.0 was used for statistical analyses.
Within-group comparisons of time points were done
using Kruskal-Wallis test. For pairwise comparisons,
built-in post hoc test of the statistical software for
Kruskal-Wallis was used. For inter-group comparisons
at each time point, Mann-Whitney U test was used. A p
value <0.05 was considered an indication of statistical
significance.
Results
Table 2 shows tensile test results of the experiments
(maximum load [load at tendon rupture]). Both groups
had improvement over time. Week 4 (p = 0.001) and
week 3 (p = 0.012) values were higher than week 1 value
in the erythropoietin group. In controls, week 4 value was
higher than week 1 value (p = 0.001) (Additional file 1).
However, groups did not differ at any of the time points.
Table 3 shows the changes in revascularization, inflam-
mation, fiber structure, and hyaline degeneration scores
and number of fibroblasts throughout the experiment
for each study group (Additional file 2). Revasculariza-
tion scores of the erythropoietin group showed a signifi-
cant decrease throughout the experiment (p = 0.012)
starting from the third week (p = 0.034) (week 4 (p =
0.034) and week 3 (p = 0.034) values were lower than
week 1 value). Although the control group also showed
a decrease in revascularization scores over time (p =
0.035), post hoc analysis did not identify a significantly
different time point. Figure 2 shows representative ser-
ial revascularization images of the two groups at differ-
ent time points with their respective semi-quantitative
revascularization scores. Fiber structure scores signifi-
cantly increased during study period in both erythro-
poietin group (week 4 > week 1, p = 0.025) and control
group (week 3 > week, p = 0.034). Number of fibro-
blasts, hyaline degeneration scores, and inflammation
scores did not change significantly throughout the
study period in either of the groups. However, groups
did not differ with regard to any of the histological
scores at any of the time points (p > 0.05 for all).
Fig. 1 Achilles tendon repair technique. a Arrows indicate the two ends of the cut tendon; b the arrow points the site of tendon repair using
modified Kessler method
Table 1 Scoring criteria for histological findings
Score
0 1 2 3
Revascularization None Mild Moderate Significant
Inflammation (percent of inflammatory cells) None ≤2 % >2–≤10 % >10 %
Fiber structures None Thin and sparse fiber structures Irregular fiber structures Regular fiber structures
Hyaline degeneration (percentage of areas with
chondroid-like cells)
None ≤10 % >10–≤30 % >30 %
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Discussion
This study examined for the first time the potential
benefit of systemic erythropoietin administration in the
healing process of the Achilles tendon in a rat experi-
mental model. Although, both erythropoietin and con-
trol groups showed biomechanical and histological
improvement over time, erythropoietin group did not
prove superior at any of the time points.
Erythropoietin is a glycoprotein hormone synthesized in
the kidneys and acts mainly on erythroid progenitor cells.
It has role in the control of erythropoiesis through its high
affinity receptor (EPOR) expressed on its target cells. Be-
sides erythroid cells, erythropoietin receptor (EPOR) has
been found on other non-hematopoietic cells such as
brain capillary endothelial cells [15], vascular smooth
muscle cells [16], myocardial cells [17], neurons [18], and
astrocytes [19]. In addition, erythropoietin is also pro-
duced in non-renal tissues such as the liver and brain [20].
Since it acts as a growth factor, it seems to stimulate mi-
tosis and induce differentiation of cell lines, including
endothelial, myocardial, smooth muscle, and mesangial
cells. These properties stimulated research on its potential
healing effects using different soft tissue models, with en-
couraging findings [8–11, 21, 22].
So far, a number of studies have examined the poten-
tial benefits of erythropoietin particularly in the healing
Table 2 Results of tensile test throughout the experiment for each study group
Week 1 Week 2 Week 3 Week 4 p
Erythropoietin group 4.9 ± 2.9 10.6 ± 4.04 19.5 ± 7.8 19.9 ± 4.7 0.001
Control group 4.0 ± 2.0 8.2 ± 2.3 12.8 ± 3.5 20.2 ± 8.7 0.002
P for intergroup difference 1.000 0.329 0.167 1.000
Data are presented as mean ± SD
In the erythropoietin group, week 4 (p = 0.001) and week 3 (p = 0.002) values are higher than week 1 value
In controls, week 4 value is higher than week 1 value (p = 0.001)
Raw data is provided in Additional file 1
Table 3 Changes in revascularization, inflammation, fiber structure, and hyaline degeneration scores and number of fibroblasts
throughout the experiment for each study group
Week 1 Week 2 Week 3 Week 4 pa
Revascularization score
Erythropoietin group 3 (3–3) 1 (1–1) 0 (0–0) 0 (0–0) 0.012
Control group 2 (1–2.5) 0.5 (0–0.5) 0 (0–0) 0 (0–0) 0.035b
P for intergroup difference 0.100 0.100 1.000 1.000
Inflammation score
Erythropoietin group 2 (2–3) 1 (0–1) 1 (0–1) 0 (0–1) 0.061
Control group 3 (2–3) 1 (0–1) 0 (0–1) 0.5 (0–1) 0.075
P for intergroup difference 0.700 1.000 0.700 0.800
Fiber structure score
Erythropoietin group 1 (0–1) 1 (1–1) 2 (2–2) 3 (3–3) 0.015
Control group 1 (1–1) 2 (2–2) 3 (3–3) 3 (3–3) 0.019
P for intergroup difference 0.700 0.100 0.100 1.000
Hyaline degeneration score
Erythropoietin group 0 (0–0) 1 (0–1) 1 (1–3) 2 (1–3) 0.051
Control group 0 (0–0) 1 (1–2) 3 (1–3) 2.5 (2–3) 0.053
P for intergroup difference 1.000 0.400 0.700 0.800
Number of fibroblasts
Erythropoietin group 22 (8–28) 40 (32–47) 54 (40–54) 27 (12–30) 0.030b
Control group 20 (16–33) 45 (27–52) 44 (30–45) 32 (30–35) 0.272
P for intergroup difference 1.000 1.000 0.400 0.200
Data are presented as median (range)
aOverall p value for differences between four time points
bDespite statistical significance for overall difference, post hoc analysis did not identify a significantly different time point
Raw data is provided in Additional file 2
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of the injuries involving musculoskeletal system, most of
them focusing on fracture healing [23–25]. In an experi-
mental mice femur fracture model, a high dose of
systemic erythropoietin (5000 U/kg/day for 6 days) was
found to be associated with improved biomechanical
properties and callus density after 2 weeks, when com-
pared to controls [23]. These findings coincided with the
expression of erythropoietin receptors in the terminally
differentiating chondrocytes in the callus, suggesting a
role for erythropoietin in early osteochondral ossifica-
tion. Another experimental study examined the effect of
a far lower dose of erythropoietin (500 U/kg/day)—si-
milar to the present study—on the healing of femoral
osteotomy and found improved biomechanical stiff-
ness and density of the periostal callus after 2 and
4 weeks, compared to controls [25]. In addition, erythro-
poietin treatment was associated with higher endosteal
vascularization and histologically more prominent bone
formation. Similarly, in a rabbit mandibular distraction
osteogenesis model, a similar systemic erythropoietin dose
resulted in better vascularization and bone healing as evi-
denced by high number of osteoblasts and osteoclasts and
a larger area of new bone formation [24]. In a recent clin-
ical study, local injection of erythropoietin to fracture site
resulted in shorter time to fracture union and lower non-
union rate, indicating a potential role in accelerating bone
healing process in human subjects [26]. Fewer studies
examined the effect of erythropoietin on the healing of
skeletal muscle healing. Rotter et al. administered
5000 IU/kg erythropoietin or saline to rats with experi-
mentally traumatized left soleus muscle and assessed
muscle recovery, microcirculation, tissue integrity, and cell
proliferation over time, using muscle contraction capacity
and immunohistochemical methods [27]. They found
improved muscle strength, circulation, and cellular regen-
eration in erythropoietin-treated mice when compared to
controls that received saline. In their experimental study,
Jia et al. showed the role of erythropoietin signaling
through non-hematopoietic receptors on skeletal myoblast
proliferation and wound healing in a mouse model of
cardiotoxin-induced muscle injury [28]. Mice with
erythropoietin receptor restricted to hematopoietic tissue
showed poor skeletal muscle healing response and higher
susceptibility to skeletal muscle injury, indicating a role of
erythropoietin signaling in skeletal muscle tissue apart
from its role in the hematopoietic system.
Our literature search revealed only a single study
examining the effects of systemic erythropoietin on ten-
don healing. In the experimental study by Uslu et al.
[12], the rat patellar tendons were surgically cut and
then repaired, and the biomechanical and histological
effects of systemic erythropoietin administration (500 U/
kg body weight, similar dose with the present study)
were compared with controls (no treatment or saline
administration). In that study, erythropoietin administra-
tion resulted in higher ultimate breaking force when
compared to controls, both at 3 and 6 weeks, suggesting
better tendon healing. Histopathological results were
somewhat conflicting, since erythropoietin seemed to
have a negative effect on fibroblast proliferation, capil-
lary vessel formation, and local inflammation (as
evidenced by lower scores reflecting less severe histo-
pathological findings), but not on collagen organization
at week 3. However, erythropoietin did not seem to have
an effect on histological parameters on week 6. In
contrast with these histological findings, erythropoietin
administration was associated with higher tissue levels of
collagen (Col) I, Col III, TGF-β1, and VEGF mRNA
Fig. 2 A representative serial revascularization images of the erythropoietin group (E1 through E3) and the control group (K1 through K3) at
different time points (week 1 through week 3) with their semi-quantitative revascularization scores. Figures at the right bottom corner denotes
revascularization scores. Hematoxylin and eosin stain, ×20 magnification. Arrows indicate vascular proliferation areas
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expressions. In that study, each experimental group had
relatively small number of animals (n = 7), as it is the
case in the present study. The present study on the
other hand, could not demonstrate a beneficial effect of
erythropoietin on Achilles tendon healing in our experi-
mental model, although improved tendon strength was
observed over time in both the study groups and
controls.
A major concern regarding systemic erythropoietin
treatment may be its possibly dose-related adverse
effects. High systemic doses of erythropoietin may result
in a prothrombotic state [29, 30], which may be particu-
larly important and life threatening for patients with
cardiovascular disease and for cancer patients. Thus, the
optimal dose and treatment duration needs to be clari-
fied. This study tested a relatively low systemic dose and
did not show any beneficial effect on tendon healing,
which is in contrast with the findings of several previous
low-dose experimental studies. Although how experi-
mental doses translate into benefits in clinical setting is
another concern, further studies with higher but safe
doses with varying treatment durations may reveal
encouraging results.
Potential beneficial effects of erythropoietin on tissue
healing may be attributed to its several physiological
functions other than controlling hematopoiesis. Research
has identified antioxidant [3], anti-apoptotic [4], anti-
inflammatory [5], and angiogenic [6] properties, all may
have potential role in tissue healing. Angiogenic proper-
ties have been attributed to a direct effect on VEGF
production and endothelial cell mitosis [29, 31]. In
addition to its angiogenic effects, it may modulate local
environment at injury site through decreasing inflamma-
tion [32] and necrosis [33], recruiting stem cells [34] and
modulating immune cell functions [35].
Regarding tendon injuries, local extracellular environ-
ment affects the process of tendon healing process,
which is characterized by inflammation, fibroplasia, and
remodeling phases. Tendon injury involves both disrup-
tion of vessels and alteration of the extracellular matrix.
Inflammatory cell infiltration and migration, angiogen-
esis, tenocyte proliferation to produce collagen and
matrix proteoglycan, and collagen reorganization takes
place after tendon injury. Although non-hematopoietic
properties of erythropoietin are expected to aid in better
revascularization, fibrosis and ultimately in better tissue
biomechanical properties, findings of this study did not
support such an association. This may be due to the
small sample size of this study, which is the main limita-
tion, resulting in small number of rats at each time
point, particularly for the assessment of histopatho-
logical changes. Alternatively, tendon tissue might differ
from other soft tissues that benefit from erythropoietin
at biochemical level, probably with regard to receptor
expression. Nevertheless, based on studies with other
tissues, erythropoietin seems to have some beneficial
effects on healing and its effect on tendon healing
process merits further investigation in trials with larger
sample sizes. Experimental and clinical studies as well as
molecular studies—for example, focusing on erythropoi-
etin receptor expression on tenocytes—would shed light
on this issue and may pave the way to helpful treatments
for the healing of the repaired tendons, which represents
a challenge in the clinical setting.
Conclusions
Findings of this study do not justify the benefit of systemic
erythropoietin administration in Achilles tendon healing
process. Further evidence from larger experimental studies
is warranted.
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